Influences of the size of lymph node metastasis on the chemoradiotherapy efficacy and prognosis for the patients after esophagectomy of thoracic esophageal squamous cell carcinoma
Guo Xinwei, Ji Shengjun, Zhou Shaobing, Gu Liang, Liu Yangchen
Department of Radiation Oncology, Affiliated Taixing People′s Hospital of Yangzhou University, Taixing 225400, China
Guo Xinwei, Ji Shengjun, Zhou Shaobing, Gu Liang, Liu Yangchen. Influences of the size of lymph node metastasis on the chemoradiotherapy efficacy and prognosis for the patients after esophagectomy of thoracic esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2018, 45(3): 148-156.
[1] Liu J, Xie X, Zhou C, et al. Which factors are associated with actual 5year survival of oesophageal squamous cell carcinoma?[J]. Eur J Cardiothorac Surg, 2012, 41(3): e7-e11. DOI: 10.1093/ejcts/ezr240.
[2] Liu Q, Cai XW, Wu B, et al. Patterns of failure after radical surgery among patients with thoracic esophageal squamous cell carcinoma: implications for the clinical target volume design of postoperative radiotherapy[J]. PLoS One, 2014, 9(5): e97225. DOI: 10.1371/journal.pone.0097225.
[3] 苏娜, 王雅棣, 李成林, 等. N0期胸段食管癌GTV长度和最大直径及体积对放疗预后影响[J]. 中华放射肿瘤学杂志, 2014, 23(1): 27-30. DOI: 10.3760/cma.j.issn.1004-4221.2014.01.007.
[4] Chen Y, Zhang Z, Jiang GL, et al. Gross tumor volume is the prognostic factor for squamous cell esophageal cancer patients treated with definitive radiotherapy[J]. J Thorac Dis, 2016, 8(6): 11551161. DOI: 10.21037/jtd.2016.04.08.
[5] 中国非手术治疗食管癌临床分期专家小组. 非手术治疗食管癌的临床分期标准(草案)[J]. 中华放射肿瘤学杂志, 2010, 19(3): 179-180. DOI: 10.3760/cma.j.issn.1004-4221.2010.03.001.
[6] Nishino M, Jagannathan JP, Ramaiya NH, et al. Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know[J]. AJR Am J Roentgenol, 2010, 195(2): 281-289. DOI: 10.2214/AJR.09.4110.
[7] Chen HL, Wu ZY, Chen JX, et al. Postoperative adjuvant therapy for resectable thoracic esophageal squamous cell carcinoma: a retrospective analysis of 426 cases[J]. Med Oncol, 2015, 32(1): 10. DOI: 10.1007/s12032-014-0417-6.
[8] Tu L, Sun L, Xu Y, et al. Paclitaxel and cisplatin combined with intensitymodulated radiotherapy for upper esophageal carcinoma[J]. Radiat Oncol, 2013, 8(1): 75. DOI: 10.1186/1748717X8-75.